Sunday, October 18, 2020 1:01:55 AM
But you know what I don't see? We've got product life cycle management efforts scheduled for next year (New patient segments, label expansion, additional dose formulations), but I don't see any serious commitment to R&D. That may be something Chappell may direct, when they're ready. But the roll-out of our commercialization is going to demand a lot of management's resources in the near term.
Still, though, if I had the education to be able to do R&D in the magical world of mAbs, the allure would compel me to forego other opportunities. It's just a field I think I would be awestruck in love with.
I had the opportunity with Corning Glass Works, after a promotion and transfer to Corning, NY, to have relatively free reign in their Sullivan Park Research Center. I was like a kid in a candy store. I loved it.
Chappell did work in two pioneering research labs. He must miss it.
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM